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Available online 06 February 2018Fasudil is a clinically approved Rho-associated protein kinase (ROCK) inhibitor that has been usedwidely to treat
cerebral consequences of subarachnoid hemorrhage. It is known to have a positive effect on animal models of
neurological disorders including Parkinson's disease and stroke. However, its cellular effect on progenitor popu-
lations and differentiation is not clearly understood. While recent studies suggest that fasudil promotes the mo-
bilization of neural stem cells (NSCs) from the subventricular zone in vivo and promotes the differentiation of the
C17.2 cerebellar neuroprogenitor line in vitro, it is unclearwhether fasudil is involved in the differentiation of pri-
mary NSCs.
Here, we tested the effect of fasudil on mouse NSCs in vitro, and observed increased gliogenesis in NSCs derived
from lateral ventricles. Upon treatment, fasudil promoted characteristics of neurogenesis including phenotypic
changes in neural outgrowth and interkinetic nuclear-likemovements as an immediate response, while Sox2 ex-
pression was maintained and GFAP expression increased. Moreover, the gliogenic response to fasudil medium
was observed in both early postnatal and adult NSC cultures.
Taken together, our results show that fasudil promotes the differentiation of NSCs into astroglial lineage, suggest-
ing that it could be used to develop novel vitro gliogenesis models and regulate differentiation for neural repair.
© 2018 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Fasudil is a ROCK inhibitor that has been shown to alleviate symp-
toms from a range of CNS disorders including subarachnoid hemor-
rhage, spinal cord injuries, cerebral stroke, Parkinson's disease,
neuropathic pain and epilepsy (Chen et al., 2013; Nakamura et al.,
2013; Satoh et al., 2012; Hara et al., 2000; Baba et al., 2010;
Impellizzeri et al., 2012; Wang et al., 2012; Mueller et al., 2005;
Shibuya et al., 1992; Villar-Cheda et al., 2012; Boyce-Rustay et al.,
2010; Inan and Büyükafşar, 2008). Although other ROCK inhibitors in-
cluding C3 transferase and Y27632 have shown similar neurogenic ef-
fects on animal models in vivo and in vitro, fasudil is the only clinically
approved ROCK inhibitor currently in use for patients suffering from
CNS disorders (Jia et al., 2016; Gu et al., 2013).
Accumulation of Rho-associated protein kinase (ROCK) has been in-
volved in a variety of neuronal functions including inhibition of axonal
regeneration, inhibition of neuronal differentiation and proliferation of
tumor cells (Chen et al., 2013; Liu et al., 2015; Compagnucci et al.,
2016; Ying et al., 2006). ROCK is a direct downstream effector of Rho,Sottile).
en access article under the CC BY-NCa member of the Rho-GTPases belonging to the Ras superfamily (Liu et
al., 2015). There are two isoforms of ROCK – ROCK1 and ROCK2, of
which the latter is mainly expressed in the central nervous system.My-
elin-associated inhibitory factors such as myelin associated glycopro-
tein, oligodendrocyte myelin glycoprotein and Nogo can activate the
Rho-ROCK signaling pathway by binding to the Nogo receptor/Lingo-
1/p75 receptor complex present in the cell membrane (Liu et al.,
2015). Activated ROCK can then phosphorylate the myosin light chain
which leads to a series of events that causes neurite retraction and col-
lapse of the growth cone in the central nervous system (Liu et al., 2015).
The result is a lack of nerve growth, neural support and axon regenera-
tion. Therefore, inhibitors for Rho-ROCK pathway are being targeted for
their potential to treat neurological disorders (Chen et al., 2013).
An in vivo study has shown that intra peritoneal administration of
fasudil in a hypoxia/reoxygenation mouse model can mobilize endoge-
nous progenitors from the SVZ, suggesting that NSCs may be fasudil-re-
sponsive (Ding et al., 2010). Moreover, a recent study reported that
fasudil could differentiate the cerebellum-derived C17.2 neural cell
line into neurons and glia in vitro. However the cellular effects of this
drug on neuroprogenitor cell populations remain unclear and there
has been no study on the response to fasudil in primary NSC cultures
in vitro. Here, we analysed the effect of fasudil on primary NSC culture-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of early postnatal and adult mouse brain tissue.
2. Methods
All reagents used were purchased from Thermoﬁsher (UK) unless
otherwise stated.
2.1. Cell culture
For primary NSC isolation, lateral ventricle tissues from postnatal
day 21 and adult mice brain were isolated from lateral ventricle tissue,
which was carefully dissected from coronal sections immersed in PBS,
transferred to a new dish to be brieﬂy minced, and then transferred to
a conical tube containing Accumax (Sigma-Aldrich, UK) for 30 min at
37 °C, with mild agitation every 10 min. The digested tissues were
then washed with PBS and centrifuged at 200g for 5 min. The cell pellet
was re-suspended in NSC medium (made from DMEM F12/Neurobasal
(1:1) medium containing 0.5% Penicillin/Streptomycin (P/S) and 0.01%
heparin, with B27 and N2 supplements, and added growth factors
bFGF and EGF (20 ng/μl)). The cellswere split usingAccutase (Sigma-Al-
drich, UK) and used within 10 passages. For differentiation, postnatal
NSCs were seeded on 0.1% gelatin coated coverslips at 50,000 cells/ml
(Adult LV-NSCs were seeded on Geltrex to reduce cell loss during im-
munostaining washes). Upon reaching conﬂuency, the medium was
changed to differentiation medium (identical to NSCmedium but with-
out growth factors), supplemented with 0.5% FCS, with or without 100
μM Fasudil (FAS, Tocris) as indicated. For neuronal differentiation, the
differentiation medium without Fasudil was supplemented with the
retinoic acid analogue 1 μM EC23 (Tocris) and 10 ng/μl BDNF (Source
Bioscience) which was referred to as retinoid-based medium (RET).
C17.2 immortalised mouse cerebellar cells were cultured in DMEM
high glucose medium supplemented with 10% FCS and 0.5% P/S. This
cell linewas used as a positive control for fasudil mediated neuronal dif-
ferentiation in vitro (Chen et al., 2015). For differentiation, C17.2 cells
were seeded onto coverslips placed at 40,000 cells/ml. After 24 h, the
medium was refreshed and supplemented with 100 μM FAS.
2.2. Neurite outgrowth analysis
Images of undifferentiated and FAS-treated cultures were captured
using Nikon microscope and images processed using ImageJ software
(www.imagej.nih.gov/ij/). Images were captured from 3 independent
biological replicates, and from each replicate 3 image sections were se-
lected for neurite outgrowthmeasurements (technical replicates). Only
the neurite lengths longer than the diameter of the cell body were con-
sidered for analysis. Total neurite length was normalised to the number
of cells visualized in each image.
2.3. Immunohistochemistry
Cells were ﬁxed in 4% ice-cold paraformaldehyde (PFA), washed
with PBS, then incubated in 0.1% Triton-X (Sigma-Aldrich), followed
by a PBS wash. Samples were then washed brieﬂy in PBT (PBS + 0.1%
Tween20 (Sigma-Aldrich)) and blockedusing5% goat serum (Sigma-Al-
drich) in PBS. Samples were incubated overnight in primary antibodies
diluted in blocking solution, using the following antibody dilutions:
Nestin (mouse monoclonal; 1:50; Dako), Sox2 (rabbit polyclonal;
1:500; EMD Millipore), βIII-Tubulin (rabbit polyclonal; 1:1000;
Abcam), GFAP (rabbit polyclonal; 1:250; Dako), S100b (1:200; Dako)
and DCX (1:500; Cell Signalling). Samples were then brieﬂy washed in
PBT and incubated for 1 h in secondary antibodies diluted in blocking
solution, with the following dilutions: Alexa Fluor 488-conjugated
goat anti-mouse (1:250), Alexa Fluor 488-conjugated goat anti-rabbit
(1:250), Alexa Fluor 594-conjugated goat anti-rabbit solution (1:20),
Alexa Fluor 647-conjugated goat anti-rabbit (1:250) followed by briefPBT wash. Samples were mounted using DAPI-containing Vectashield
mounting solution (Vector Laboratories, UK) and imaged with a Nikon
Eclipse 90i ﬂuorescent microscope. Alternatively, immunostained sam-
ples were incubated in DAPI solution and imaged using Operetta High-
Content Imaging System (Perkin Elmer, UK). Quantitative analysis of
immunoﬂuorescencewas performed using the ImageJ software (for im-
ages captured byNikon 90imicroscope) or theHarmony Image Analysis
system (for images captured by Operetta). For ImageJ, immunostaining
was quantiﬁed by determining the area of intensity of particular anti-
body ﬂuorescence over the area covered by DAPI ﬂuorescence for each
image. Immunoﬂuorescent quantiﬁcation of samples for particular anti-
bodies were then normalised to their respective day 0 samples. For im-
ages processed by Harmony Software, total ﬂuorescence was calculated
and averaged from9 randomly selectedﬁelds of viewperwell. All quan-
tiﬁcations were analysed above the negative threshold set calculated
from negative control ﬂuorescence.
2.4. Reverse transcriptase PCR (RT-PCR) and quantitative PCR (qPCR)
Cells were processed using TRI Reagent (Sigma-Aldrich) and total
RNA extracted using RNA Clean and Concentrator (Zymo Research) fol-
lowing the manufacturer's protocols. DNAse 1 treatment was applied
and reverse transcription (RT) was performed using 1 μg RNA with
the Superscript 3 RT enzyme kit, following manufacturer's protocol.
PCR was performed using the Platinum Taq DNA polymerase kit and
the following primers: Clathrin6k (F: 5′-GACAGTGCCATCATGAATCC-
3′, R: 5′-TTTGTGCTTCTGGAGGAAAGAA-3′), Nestin (F: 5′-AGAGTCA
GATCGCTCAGATCC-3′, R: 5′-GCAGAGTCCTGTATGTAGCCAC-3′), Sox2
(F: 5′-GGCGGCAACCAGAAGAACAG-3′, R: 5′-GCTTGGCCTCGTCGA
TGAAC-3′), GFAP (F: 5′-CTCAATGCTGGCTTCAAGGAG-3′, R: 5′-GG
ATCTCCTCCTCCAGCGA-3′) and βIII-tub (F: 5′-GGCCTCCTCTCACAAG
TATGT-3′, R: 5′-CAGGGAATCGAAGGGAGGTG-3′). Tubes containing no
RNA and no enzyme controls were used in parallel reactions to conﬁrm
the absence of contamination. ImageJ software was used to calculate
band intensities from gel and normalise to Clathrin6k (housekeeping
gene) to provide semi-quantiﬁcation of gene expression. For qPCR,
Power SYBR Green PCR Master Mix (Applied Biosystems) was used.
Gene expression was normalised against expression of Clathrin6k and
calculated using 2−ΔΔCt. The following primers were used: Clathrin6k
(F: 5′-AGATTCTGCCCATTCGCTTTC-3′, R: 5′-TCAGTGCAATCACTT
TGCTGG-3′), Nestin (F: 5′-AGAGTCAGATCGCTCAGATCC-3′, R: 5′-
GCAGAGTCCTGTATGTAGCCAC-3′), Sox2 (same as mentioned above
for RT-PCR), βIII-tub (F: 5′-GCGCCTTTGGACACCTATTCA-3′, R: 5′-
GCCCTCCGTATAGTGCCCT-3′), GFAP (F: 5′-GAGGAGTGGTATCGGT
CTAAGTTTG-3′, R: 5′-GCCGCTCTAGGGACTCGTT-3′). Primers were
validated using mouse brain tissue as positive control, and mouse liver
tissue as negative control. Mean gene expression (2−ΔΔCt) was calcu-
lated between two independent experiments with three replicates and
graphed with standard deviation (SD).
2.5. Metabolic activity assay
Presto Blue (PB) kit was used to analyse themetabolic activity of dif-
ferentiating cells according to manufacturer's instructions. NSCs and
C17.2 cells were seeded at 50,000 and 15,000 cells per well in 24-well
plates, or 5000 and 1000 cells per well in 96 well plates, respectively.
To normalise presto blue ﬂuorescence to cell numbers, cell counts
were performed with ImageJ software using 3 randomly selected re-
gions on brightﬁeld images for each of the 3 replicate wells analysed
per condition. DNA quantitation was carried out using the PicoGreen
dsDNA assay (according to manufacturer's protocol). To determine the
change in cell number on day 2 and day 4 FAS-treated and untreated
samples, all cell count values for treated samples were normalised to
the cell count of day 0 untreated samples. To determine the change in
metabolic activity on day 2 and day 4 FAS-treated and untreated
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normalised to the metabolic activity of day 0 untreated samples.
2.6. Cell motility analysis
Cells were cultured in 96-well plates in biological triplicates and live
imaging was performed using the Operetta High-Content Imaging sys-
tem with Harmony software. Live images were taken every 3 s for 2 h
and 45 min from one ﬁeld of view in each well in brightﬁeld and digital
phase contrast modes to enable segmentation and tracking of cells. The
building blocks for analysis were as follows: Input Image - Filter Image –
Find Cells – Track Objects – Calculate Kinetic Properties – Calculate
Properties – Calculate Track Properties – Deﬁne Results. Digital phase
contrast images were used for tracking analysis and ﬁltering using the
sliding parabola option under ‘Filter Image’ block. The ‘Track Properties’
module was used to determine ‘Accumulated Distance’ (normalised to
track count), ‘Start/End Type’, ‘Number of Time-points’, ‘Displacement’,
and ‘Speed’ parameters of the tracked cells. The percentage of cells
tracked from ‘BEGIN’ to ‘END’ (B-E type) was deﬁned as cells that
could be tracked throughout all timepoints without division/fusion
events or any imaging hindrance (cosmos/border). The percentage of
cells tracked from ‘SPLIT’ to ‘SPLIT’ (S-S type) was deﬁned as actively di-
viding cells undergoing division at least twice while being tracked. A
supplementary ﬁgure explains the cell track types graphically (Supple-
mentary Fig. 1). The accumulated distance (normalised to track count)
of B-E type tracks was used to determine changes in cell migration.
2.7. Statistical analysis
All experiments were run in triplicates using separate cultures, with
at least three internal repeats. Mean and SD were analysed using either
GraphPad Prism orMicrosoft Excel. One way ANOVAwith Tukey's mul-
tiple comparison test was run to determine the statistical signiﬁcance
for all analysis unless otherwise speciﬁed. Statistical signiﬁcance level
was set for *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001. Complete
statistical data sets for all the experiments are included in a Supplemen-
tary excel sheet (Supplementary Sheet 1).
3. Results
3.1. Fasudil alters the metabolic activity and morphology of postnatal NSCs
The effect of fasudil treatment on postnatal NSCs was ﬁrst analysed
through metabolic activity measured of cultures over 4 days as an indi-
cation of cell health (Fig. 1A). C17.2 cells were used as a positive control
for FAS mediated neural differentiation according to a recently pub-
lished study (Chen et al., 2015). 100 μM FAS was seen to increase the
metabolic activity of NSCs and C17.2 (Fig. 1A). InNSCs, FAS addition pro-
duced a signiﬁcant and sustained increase in metabolic activity at both
time points (Fig. 1A), while in C17.2 samples FAS treatment only
showed a signiﬁcant metabolic increase only on day 2 (Fig. 1B).
In addition, effects on cell morphology were observed upon treat-
ment (Fig. 1). Brightﬁeld images of FAS-treated samples at day 2 and
day 4 showed cytoskeletal changes with increased neurite outgrowth
in both NSCs and C17.2 cells, compared to day 0 controls (Fig. 1C).
Total neurite length increased signiﬁcantly from day 2 to day 4 of FAS
treatment for both cell types, and this increase was more pronounced
in C17.2 cells (Fig. 1D). We noticed that NSCs showed smooth radial-
like elongated neural outgrowth with less or no branching compared
to C17.2 cells (Fig. 1C). To further investigatewhether the radial-like un-
branched neural extensions observed in FAS-treated NSCs were of neu-
ronal origin, βIII-tubulin immunostaining was used. A supplementary
ﬁgure contains information that revealed low βIII-tubulin expression
in FAS-treated NSCs compared to C17.2 cells (Supplementary Fig. 2).
βIII-tubulin expression showed amoderate increase in NSC neurite out-
growth by day 4 (Supplementary Fig. 2A–B), suggesting the majority ofNSCs after fasudil treatment did not produce neuronal-like outgrowth
but rather radial-like projections. By contrast, C17.2 showed stronger
βIII-tubulin immunoreactivity with signiﬁcant increase on day 2 and
day 4 with FAS medium (Supplementary Fig. 2C–D).
3.2. Fasudil increases the expression of GFAP in postnatal NSCs
To further investigate changes observed in vitro in response to FAS-
based medium, expression of NSC markers Nestin and Sox2, glial
marker GFAP, and neuronal marker βIII-Tubulin were analysed over
the 4-day FAS treatment by immunostaining (Fig. 2). Undifferentiated
day 0 postnatal NSCs showed moderate Nestin and strong Sox2 signal,
and were rare of GFAP or βIII-Tubulin expression (Fig. 2A). Upon FAS-
treatment, there was a striking loss of nestin signal, and a signiﬁcant in-
crease in Sox2 detection in day 2 and day 4 (all compared to day 0 con-
trol) (Fig. 2B). FAS-treated NSCs also displayed signiﬁcantly higher
levels of GFAP expression on day 2 and day 4 compared to untreated
control (Fig. 2B), while βIII-Tubulin signal, which was generally low,
was reduced on day 2 but signiﬁcantly increased by day 4 FAS-treat-
ment. Taken together these results hinted that fasudil promoted
gliogenesis of NSCs by increasing the expression of GFAP and Sox2
(markers of proliferating NSCs and reactive astrocytes) with concomi-
tant reduction in Nestin and low βIII-Tubulin expression (markers of
neuronal progenitors and early neural lineage, respectively).
Supplementary Fig. 3 shows the diverse effect of fasudil on C17.2
cells while Supplementary Figs. 4 and 5 show RT-PCR results of tested
neural markers and immunohistochemistry of overgrown cultures re-
spectively, complementing the gliogenic effect of fasudil on primary
NSCs (Supplementary Figs. 3–5). In contrast to NSCs, fasudil treatment
of C17.2 cells promoted the appearance of βIII-Tubulin-positive cells
(Supplementary Fig. 3). Nestin signal was low in these cells but showed
a signiﬁcant increase at day 2 and day 4 (Supplementary Fig. 3B). This
was accompanied by a moderate decrease in Sox2 detection on day 4
(Supplementary Fig. 3B). GFAP expression was observed to be weak
throughout the treatment course. This suggests that fasudil promoted
neuronal rather than glial lineage differentiation in C17.2 cells.
RT-PCR performed to complement the immunodetection data con-
ﬁrmed the trends observed. Accordingly, FAS-treated NSCs showed sig-
niﬁcant increases in sox2 and GFAPmRNA (Supplementary Fig. 4A–B)
while Fas treated C17.2 showed a moderate decrease in sox2 and a sig-
niﬁcant increase in βIII-tubulin (Supplementary Fig. 4C–D).
We then compared the GFAP and βIII-Tubulin expression of day 2
and day 4 undifferentiated controls with FAS-treated NSCs and C17.2
cells (Supplementary Fig. 5). Day 2 FAS-treated NSCs showed higher
levels of GFAP signal compared to all untreated controls, while βIII-Tu-
bulin was always detected at low levels (Supplementary Fig. 5A–B).
FAS-treated C17.2 showed very low levels of GFAP when compared to
untreated controls in contrast to βIII-Tubulin expression which showed
high level signals at both FAS-treated as well as overgrown cultures
(Supplementary Fig. 5C–D). This shows that FAS-treated samples differ-
entiated in a unique manner different from that of spontaneous differ-
entiation of overgrown cultures in vitro.
3.3. Fasudil medium promoted radial interkinetic nuclear-like migration of
postnatal NSCs
In order to further analyse the phenotypic changes in NSCs treated
with FAS-based medium, the dynamics and migratory properties of the
cells in culture were monitored by time-lapse microscopy. In the mam-
malian brain, migrating NSCs are known to express GFAP and show ra-
dial-like morphology (Malatesta et al., 2008; Doetsch et al., 1999;
Kulikova et al., 2011; Del Bene, 2011; Spear and Erickson, 2012a). Radial
glia populations display INM (interkinetic nuclear movement), a distinct
migration pattern of the cell body along the radial-bidirectional cytoplas-
mic elongation, between the basal and apical layer of ventricular zone
(Spear and Erickson, 2012a, Spear and Erickson, 2012b).
Fig. 1. Change inmetabolic activity and neurite outgrowth upon FAS treatment. (A–B) Normalisedmetabolic activity measurements of postnatal NSCs (A) and C17.2 (B) cultures at 2 and
4 days of treatmentwith 100 μMFAS. All sample have been normalised to day 0 undifferentiated samples (dotted line). (C–D) Changes in neurite outgrowth upon FAS treatment analysed
bybrightﬁeld images (C),with corresponding image analysis of neurite length of NSCs andC17.2 (D). Zoomed inboxes in (C) showdetails at highermagniﬁcation. Arrows show the radial-
like morphology of cells. Scale bar: 250 μm. Statistical signiﬁcance: *p b 0.05.
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treatment, NSCs were observed to form denser colonies and exhibited
a radial-likemigratory pattern suggestive of INMby day 2 (Fig. 3A). No-
tably, there was a signiﬁcant increase in trackable migratory cells (B-E
type) by day 4 (Fig. 3B). Supplementary video ﬁles show the radial-
like movement of NSCs after FAS-treatment (Supplementary Videos
1–2). C17.2 cells showed a signiﬁcant increase in trackable migratory
cells both day 2 and day 4, however most C17.2 cells showed aFig. 2.Marker expression analysis in postanatal NSCs exposed to fasudil. (A) Immunoﬂuoresce
tubulin (green) in undifferentiated day 0 and FAS-treated postnatal NSCs at day 2and day 4
image analysis (dotted line is day 0). Scale bar 250 μm. *p ≤ 0.05.tangential migratory pattern on day 2 of FAS treatment (Fig. 3A),
displaying a ‘crawling’ behavior with short extentions. Additional
video ﬁles show the migrational behaviour by C17.2 cells (Supplemen-
tary Video 3). The proportion of cells undergoing division (S-S type) sig-
niﬁcantly decreased in all FAS-medium samples compared to their day 0
counterparts (Fig. 3C), indicating FAS medium reduced the percentage
of dividing cells or delayed the cell division. This suggested that, expo-
sure to FAS medium promoted a more radial-like migratory phentypence images showing the expression of Nestin (green), Sox2 (red), GFAP (green) and βIII-
. DAPI used as nuclear counterstain (blue). (B) Corresponding signal quantitation using
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Fig. 4.Morphological andmetabolic response of adult NSCs during RET- and FAS-differentiation on day 2 and day 10. (A)Morphological changes- arrows show the branching neurites in RET-
treated adult NSCs vs ﬂattened radial-like outgrowth in FAS-treated adult NSCs at day 10. Scale bar 250 μm. (B) Metabolic activity normalised to DNA content (dotted line is day 0). *p b 0.05.
81Z.A. Nizamudeen et al. / Stem Cell Research 28 (2018) 75–86in postnatal NSCs, different from the predominantly tangential-like mi-
gratory phenotype observed in treated C17.2 cells.
Finally, the total accumulated distance travelled by the non-dividing
migratory cells in NSCs under FAS medium was found to rise sharply
compared to day 0 control (Fig. 3D), while for C17.2 cells, the distance
travelled under FAS mediumwas signiﬁcantly lower than its day 0 con-
trol (Fig. 3D).
3.4. Fasudil-based differentiation compared to standard retinoid-based
differentiation
Adult NSCs aremore restricted in terms of differentiation andmigra-
tion than embryonic and early postnatal NSCs (Obernier et al., 2014). In
order to determine how FAS treatment may affect adult NSCs in culture
and to compare its efﬁciency to that of conventional neuronalFig. 3. Comparative time-lapse analysis of postnatal NSCs and C17.2 cells upon treatment with FA
nucleo-kinetic locomotion of day 2 treated NSCs and tangential locomotion of day 2 treated C17.2 c
the tracking of three independent cells in the images. White arrows show the radial-like morphol
NSCs. Scale bar 50 μm. (B) Percentage of trackablemigratory cells (B-E type) in NSCs and C17.2 sam
(D) Quantitative analysis showing the total distance migrated by postnatal NSCs and C17.2 cells tdifferentiating protocols involving a retinoic acid analogue (RET),
adult NSCs were treated in vitro with both FAS-based and RET-based
media for 10 days and monitored for metabolic and differentiation re-
sponses (Fig. 4). Both differentiation conditions were associated with
rapid changes in cell morphology. By day 10, NSCs in RET medium
showed mature neuronal morphologies with branched dendrites
while NSCs in FAS medium showed ﬂat morphological properties with
less branching (Fig. 4A). There was no signiﬁcant difference in cellular
metabolic activity between the FAS-based and theRET-based conditions
at day 2 and day 10 (Fig. 4B). Also, there was no signiﬁcant reduction in
metabolic activity in both FAS- and RET- differentiation compared to
day 0 undifferentiated controls (Fig. 4B).
Based on these observations, NSC marker analysis was performed
to evaluate potential phenotypic differences under the two differen-
tiation regimes on day 10 in vitro. A supplementary ﬁgure containsS medium. (A) Morphological changes of postnatal NSCs and C17.2 cells in vitro. Example of
ells. T0, T25, T50 represent sequential time-points. Red, green and yellowmarkings represent
ogy of cells. The yellow arrow shows the denser colony formed during FAS differentiation of
ples. (C) Percentage of dividing cells (S-S type) tracked in postnatal NSCs and C17.2 samples.
reated with FAS medium vs. undifferentiated cells. *p b 0.05.
Fig. 5.Nestin and Sox2 expression in adult NSCs under FAS- and RET-differentiation protocols. (A)Nestin (green) and Sox2 (red) immunostaining at day 0 and day 10 of treatment and (B)
corresponding image quantitation analysis (dotted line is day 0). DAPI used as nuclear counterstain (blue). Scale bar 200 μm. *p b 0.05.
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(Supplementary Fig. 6). Analysis of NSC marker expression indicated
that both protocols equally reduced the expression of Nestin at day
10 (Fig. 5A–B). RET medium produced a marked reduction of Sox2
expression by day 10, while FAS medium increased the expression
of Sox2 on both day 2 (Supplementary Fig. 6A–B) and day 10
(Fig. 5C–D).3.5. Divergent differentiation responses of adult NSC under FAS- and RET-
based conditions
Further analysis of lineage markers GFAP, βIII-Tubulin, S100b and
DCX immunodetection was carried out to reﬁne the phenotypic
differences between the two treated NSC populations (Fig. 6 and
Supplementary Fig. 7A–B). While GFAP expression increased in both
FAS and RET treatments, cells under FASmediumdisplayed signiﬁcantly
higher expression by day 10, with an elongated radial-like morphology
that was not observed in cells grown in RET medium (Fig. 6A–B).
Expression of the neuronal marker βIII-Tubulin showed signiﬁcant re-
duction in FASmedium, in contrast to the RET conditionwheremultiple
βIII-Tubulin positive neurons were observed (Fig. 6A–B). Adult NSCs
were further stained for S100b and DCX, markers for mature astrocytes
and migrating neuroblasts, respectively. While S100b expression was
increased to comparable levels in both treatments, expression of the
neuronal marker DCX was only detected in RET medium (Fig. 6A–B).
qPCR analysis of these markers at day 10 (Fig. 7) conﬁrmed transcrip-
tional changes for nestin, sox2, GFAP and βIII-tubulin during FAS- and
RET-based differentiation in line with the protein detection results,
emphasizing the divergent effect of these 2 treatments on sox2 and
βIII-tubulin expression inNSCs. A supplementary ﬁgure contains the im-
munohistochemistry and qPCR results for day 2 of NSC differentiation
(Supplementary Fig. 7).4. Discussion
Fasudil is a ROCK inhibitor that has been shown to alleviate symp-
toms from a range of CNS disorders (Chen et al., 2013). Fasudil has
been reported to improve stroke protection and blood ﬂow after cere-
bral ischaemia by increasing NO (nitric oxide) production and eNOS
(endothelium-derived NO synthase) expression (Rikitake et al., 2005).
In experimental autoimmune encephalomyelitis, fasudil has been
shown to delay the onset and severity of the disease by shiftingmicrog-
lia to an anti-inﬂammatory M2 phenotype that promotes tissue repair
(Hou et al., 2012). Moreover, studies have suggested that fasudil can
protect neurons and mobilize NSCs in in vitro ischaemic models by
activating astrocyte secretion of granulocyte-colony stimulating factor
(G-CSF) and inhibiting glutamate induced neurotoxicity (Ding et al.,
2010; Huang et al., 2009; Yamashita et al., 2007). Recently, it has been
shown that fasudil can mobilize endogenous NSCs in vivo and differen-
tiate the C17.2 neural progenitor cell line in vitro (Ding et al., 2010; Chen
et al., 2015). Taken together, these studies suggested a role for fasudil in
NSC response and neurogenesis.
The use of fasudil has been reported in a variety of established neural
and tumor cell lines at different concentrations (Compagnucci et al.,
2016; Ding et al., 2010; Chen et al., 2015; Huang et al., 2009;
Yamashita et al., 2007; Tonges et al., 2012; Tatenhorst et al., 2016;
Tilson et al., 2015; Roloff et al., 2015; Takata et al., 2013; Deng et al.,
2010; Lingor et al., 2007). Recently, C17.2 cerebellar progenitor cell
line was used to study the differentiation effect of fasudil (Chen et al.,
2015). Itwas shown that thedifferentiationwasmost rapidwhen a con-
centration of 100 μM FASwas used, which resulted in the production of
neuronal cells expressing DCX (Chen et al., 2015). Using the same con-
centration,we showed that fasudil can differentiate C17.2 cells into βIII-
tubulin neuronal cells, thereby conﬁrming its effect. Interestingly, the
differentiation effect of fasudil on primary NSCs had not so far been in-
vestigated. A previous study investigating the inhibitory effect of Rho-
Fig. 6. GFAP, βIII-tubulin, s100b and DCX expression (red) in adult NSCs under FAS- and RET-differentiation protocols. (A) Immunoﬂuorescence images at day 0 and day 10 of treatment
(arrows indicate elongated radial-like neural outgrowth inGFAP positive cells) and (B) corresponding image quantitation analysis (dotted line is day 0). DAPI used as nuclear counterstain
(blue). Scale bar 200 μm. *p ≤ 0.05.
83Z.A. Nizamudeen et al. / Stem Cell Research 28 (2018) 75–86kinase on an in vitromodel of Parkinson's disease reported 100 μM FAS
to be toxic to primary midbrain neurons by reducing their cell number
(Tonges et al., 2012), suggesting primary neural cells may be sensitive
to this concentration of fasudil. Here however, we did not observe sig-
niﬁcant signs of reduced viability or impaired metabolic activity, indi-
cating the dose of 100 μM FAS did not compromise the integrity of
primary NSC cultures.
Fasudil treatmentwas observed to push the primary NSCs towards a
gliogenic phenotype with radial-like properties. Radial glial NSCs pres-
ent during development and radial glia-like NSCs present in the adultmammalian brain have shown potential to form neurons in vivo that in-
tegrate within the surrounding brain tissue and provide functional sup-
port during development, adult neurogenesis and tissue damage
(Bignami and Dahl, 1974, Doetsch et al., 1999, Campbell and Gotz,
2002, Hutton and Pevny, 2011, Götz et al., 2015, Faiz et al., 2015).
Upon proliferation and prior to differentiation, these cells are reported
to express the markers GFAP and Sox2 (Bignami and Dahl, 1974,
Doetsch et al., 1999, Campbell and Gotz, 2002, Hutton and Pevny,
2011, Götz et al., 2015). Here, we show that the differentiation of pri-
mary NSCs in the presence of fasudil lead to a loss of Nestin expression
Fig. 7. qPCR analysis of adult NSCs in FAS- and RET-basedmedium on day 10 of differentiation under FAS- and RET- differentiation protocols forNestin, Sox2, GFAP and βIII-tub (dotted line
is day 0). *p b 0.05.
84 Z.A. Nizamudeen et al. / Stem Cell Research 28 (2018) 75–86and an increase in Sox2 and GFAP expression in postnatal and adult
NSCs in vitro. NSCs in vivo have the ability to migrate during CNS devel-
opment or in the adult brain in response to injury.Whenmonitoring the
migratory pattern of primary postnatal NSCs, an increase in migratory
behaviour was observed in response to FAS medium. At the early
stage of treatment, postnatal NSCs exhibited INM, with the characteris-
tic movement of cell soma along radial extensions, a phenotype associ-
ated with radial glia known to modulate various stages of neural
development including epithelial remodelling, maintenance of epithe-
lial structure and polarity, and neural proliferation and differentiation
(Spear and Erickson, 2012a, Spear and Erickson, 2012b, Glaser and
Brüstle, 2005). FAS-treatment thus induced NSCs to display gene ex-
pression and migratory characteristics of radial-glial progenitors in
vitro, and promoted a gliogenic phenotype. This protocol produced
minimal neurogenic response, indicating the potential of fasudil as a
pro-neuroglial agent. Protein and transcript detection showed rare
expression of neuronal markers upon treatment, in contrast to the reti-
noid-based neuronal differentiation protocol, which induced the ex-
pression of βIII-tubulin and DCX in culture.
We observed an increase of Sox2 expression by day 10 of FAS-treat-
ment, which contrastedwith the response to RET-treatment. Sox2 plays
a vital role in NSCproliferation and regulation (Hutton and Pevny, 2011;
Cimadamore et al., 2013; Episkopou, 2005), and has been reported to in-
hibit neuronal differentiation in the mouse neocortex, unless the Notch
pathway is blocked (Bani-Yaghoub et al., 2006). A recent study has
shown that overexpression of Sox2 reduced the number of MAP2 posi-
tive neurons in human pluripotent NT2/D1 cells in vitro (Klajn et al.,
2014), while astrocytes retained Sox2 expression along with GFAP. It
is thus possible to speculate that fasudil may promote gliogenesis in
NSCs by increasing Sox2 expression. Recently, fasudil has beensuggested to be involved in modulating major NSC signaling pathways
including Notch and NF-kB (Chen et al., 2015; Okamoto et al., 2010).
Notch signaling acts as a molecular switch in regulating neural stem
cell (NSC) lineage determination in vivo and in vitro, by promoting
gliogenesis, self-renewal of NSCs, and inhibiting neuronal differentia-
tion (Zhou et al., 2010). Fasudil has also been known to modulate
NFκB by inhibiting IL-1–induced activation of NFκB in a rat model of
rheumatoid arthritis (Okamoto et al., 2010; Sato et al., 1998). In NSCs,
inhibition of NF-kB has been shown to increase expression of NSC
markers Nestin and Sox2 while inhibiting neuronal differentiation in
vitro (Zhang et al., 2012). Itwill thus be of interest to determinewhether
fasudil's effect on Sox2 expression in primary NSCs may thus be medi-
ated through its effects on the Notch and/or NFκB pathways.5. Conclusion
The present study explored the effects of fasudil on NSC cultures de-
rived from mouse SVZ. Fasudil was observed to promote neural out-
growth of primary neural stem cells. Immunodetection and RT-PCR
have provided evidence that fasudil treatment promotes enhanced
gliogenesis of postnatal NSCs, and real-time imaging showed that
fasudil treatment promotes radial-like inter-kinetic nuclear movement
in postnatal NSCs. A similar effect was observed in adult NSCs, as fasudil
promoted gliogenesis of adult NSCs with increase in Sox2 expression
and absence of neuronal markers βIII-tubulin and DCX. These results
provide the ﬁrst evidence that fasudil can be used for the treatment of
primary NSCs in culture with no toxicity, and can promote differentia-
tion towards a gliogenic phenotype, thus contributing to the develop-
ment of in vitromodels of neural differentiation.
85Z.A. Nizamudeen et al. / Stem Cell Research 28 (2018) 75–86This study shows that fasudil treatment applied to primary NSCs
provides an efﬁcient model to analyse the key aspects of in vivo
gliogenesis. In addition to radial glia, reactive astrocytes in the adult
brain also express GFAP and Sox2 and show proliferative andmigratory
response towards injury (Götz et al., 2015; Buffo et al., 2008). Here we
report that fasudil-treated primary NSCs share the expression andmor-
phological patterns of radial aswell as reactive gliosis, two fundamental
aspects of in vivo gliogenesis. GFAP and S100b detection highlighted the
gliogenic differentiation of NSCs, and future characterisation of this
newly identiﬁed FAS-mediated response will help determine whether
fasudil can promote the appearance of speciﬁc glial subtypes such as
oligodendrocytes.
Fasudil-treated NSCs can be used as a model to study INM of NSCs in
vitro, providing a rapid and efﬁcient procedure compared to tissue slice
culture and in vivo studies (Kulikova et al., 2011; Tsai et al., 2010; Marin
et al., 2010). Future applications could include themolecular character-
isation of INM processes by combining this method with the recently
published cell cycle staging protocol using high-content screening
(Del Bene, 2011; Roukos et al., 2015; Cecchini et al., 2012).
Our results also suggest that fasudil's target, the Rho/ROCK cascade,
could be an important NSC regulatory pathway. Furthermore, fasudil
has also been suggested to inhibit other functional kinases including
protein kinase N1 (PKN1), protein kinase C (PKC), cyclic nucleotide de-
pendant protein kinases (PKA and PKG) and Ca2+/calmodulin depen-
dant myosin light chain kinase (MLCK) in a concentration dependant
manner, resulting in off-target effects with respect to ROCK inhibition
(Asano et al., 1989; Fajardo et al., 2014; Scott, 1991; Dugan et al.,
1999). It will therefore be necessary to investigate to what extent
ROCK inhibitionmight be themainmechanism for the fasudil-mediated
gliogenic differentiation observed in NSCs, in order to further exploit
this pharmacological pathway and its potential to regulate and control
stem cell populations for CNS repair strategies.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.scr.2018.02.001.
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